^
Association details:
| Biomarker: | EGFR exon 21 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Conmana (icotinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial
Published date:
07/16/2021
Excerpt:
...confirmed activation mutation in exon 19 or exon 21 of the EGFR gene...receive either oral icotinib 125 mg thrice daily for 2 years or four 21-day cycles of intravenous chemotherapy...Median disease-free survival was 47·0 months (95% CI 36·4–not reached) in the icotinib group and 22·1 months (16·8–30·4) in the chemotherapy group...icotinib significantly improves disease-free survival and has a better tolerability profile in patients with EGFR-mutant stage II–IIIA NSCLC...
Secondary therapy:
cisplatin + vinorelbine tartrate; cisplatin + pemetrexed
DOI:
https://doi.org/10.1016/S2213-2600(21)00134-X
Trial ID:
Source:
Title:
Routine-Dose and High-Dose Icotinib in Patients with Advanced Non–Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE Trial
Excerpt:
Increasing the dose of icotinib significantly prolonged the median PFS (mPFS) in patients with exon 21 L858R mutation from 9.2 months to 12.9 months...High-dose icotinib improved mPFS and ORR in patients with NSCLC harboring 21-L858R mutation with acceptable tolerability, which could be a new therapeutic option for this patient population.
DOI:
10.1158/1078-0432.CCR-19-3064
